-
公开(公告)号:US20110158945A1
公开(公告)日:2011-06-30
申请号:US12301961
申请日:2007-06-01
申请人: John W. Barrett , Grant McFadden
发明人: John W. Barrett , Grant McFadden
CPC分类号: A61K35/768 , A61K35/76 , C12N7/00 , C12N2710/24032 , C12N2710/24062 , C12N2710/24071
摘要: Myxoma viruses that are deficient in the activity of a Myxoma virus protein selected from the group consisting of M11L, M063, M 136, M-T4 and M-T7 are useful for treating cancer.
摘要翻译: 缺乏选自M11L,M063,M 136,M-T4和M-T7的粘液瘤病毒蛋白的活性的粘液瘤病毒可用于治疗癌症。
-
公开(公告)号:US08512713B2
公开(公告)日:2013-08-20
申请号:US12301961
申请日:2007-06-01
申请人: John W. Barrett , Grant McFadden
发明人: John W. Barrett , Grant McFadden
IPC分类号: A61K39/275 , C12N7/01
CPC分类号: A61K35/768 , A61K35/76 , C12N7/00 , C12N2710/24032 , C12N2710/24062 , C12N2710/24071
摘要: Myxoma viruses that are deficient in the activity of a Myxoma virus protein selected from the group consisting of M11L, M063, M 136, M-T4 and M-T7 are useful for treating cancer.
摘要翻译: 缺乏选自M11L,M063,M 136,M-T4和M-T7的粘液瘤病毒蛋白的活性的粘液瘤病毒可用于治疗癌症。
-
公开(公告)号:US20110288004A1
公开(公告)日:2011-11-24
申请号:US12993191
申请日:2007-06-21
IPC分类号: A61K38/16 , C12N15/63 , C12N5/10 , C12P21/00 , C07K14/065 , A61P29/00 , A61P11/00 , A61P27/14 , A61P17/00 , A61P11/06 , A61P9/00 , A61P9/10 , A61P25/00 , A61P3/10 , A61P13/12 , A61P35/02 , A61P25/28 , A61P19/02 , A61P7/06 , A61P35/00 , C07H21/00 , C07K19/00 , A61K31/7088 , A61P37/02 , A61P17/10 , A61P37/04 , A61P11/02 , A61P37/06 , A61P1/16 , A61P1/18 , A61P1/00 , A61P43/00 , C12N5/09
CPC分类号: A61K48/00 , A61K38/162 , C07K14/005 , C07K2319/02 , C07K2319/21 , C07K2319/41 , C12N2710/24022 , Y02A50/463
摘要: The invention features polypeptide and polynucleotide sequences based on the 134R sequence. In some embodiments, these sequences include a heterologous signal sequence, such as the myxoma virus T7 signal sequence. The invention also features methods for treating immunological disorders and neoplasms (e.g., cancer) using the polypeptides and nucleotides described herein. Finally, the invention features fusion proteins including the myxoma virus T7 signal sequence.
摘要翻译: 本发明的特征在于基于134R序列的多肽和多核苷酸序列。 在一些实施方案中,这些序列包括异源信号序列,例如粘液瘤病毒T7信号序列。 本发明还涉及使用本文所述的多肽和核苷酸治疗免疫疾病和赘生物(例如癌症)的方法。 最后,本发明的特征是融合蛋白包括粘液瘤病毒T7信号序列。
-
-